Sleep Disorders
Avadel’s LUMRYZ Approval Upheld in Court
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) affirmed a prior decision of the U.S. District Court for the District of Columbia (the “District […]
Streamline Your Patient Intake Process
A significant number of people in America are walking around with undiagnosed sleep disorders. Recent studies indicate 14.5 percent of adults in the U.S. have difficulty falling asleep, and 17.8 percent had difficulty staying asleep.1 While these alarming statistics highlight the urgent need for sleep disorder testing and treatment nationwide, […]
Harmony Strengthens Patent With ANDA Settlement
Harmony Biosciences Holdings, Inc., today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will […]
Avadel’s LUMRYZ Receives FDA Orphan Drug Designation for Idiopathic Hypersomnia
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may be […]
Avadel Pharmaceuticals Presents New Data on LUMRYZ ER at SLEEP 2025
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 […]
Are We Truly Open to Change in the Approach to OSA?
Although there are more than half a billion individuals worldwide affected by moderate to severe obstructive sleep apnea (OSA), the vast majority still remain undiagnosed and many are untreated.1-2 Healthcare in the United States is facing shortages at every level—and these shortages are projected to increase sharply over the next […]
The Diagnostic Journey for Narcolepsy
In previous editions, we’ve talked a lot about how diagnosis is only the first part of the journey with narcolepsy. It’s true that there are many pieces to managing the disorder that follow, but that diagnosis is something we really want to hone in on in this edition. The information […]
EnsoData partners with ABM to add Positional Data to EnsoSleep PPG
EnsoData, a leader in healthcare AI technology, is partnering with Advanced Brain Monitoring (ABM) to add position data captured by ABM’s Night Shift sleep positioner into the FDA-cleared EnsoSleep PPG home sleep test (HST). Adding positional data to EnsoSleep PPG offers providers accurate supine AHI severity insights, leading to better […]
Apnimed Announces SynAIRgy Phase 3 Results
Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of Apnimed’s lead […]













